Goldman Sachs analyst maintained a Hold rating on Innate Pharma today. The company’s shares closed yesterday at $1.95.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma has an analyst consensus of Hold, with a price target consensus of $5.00, a 156.41% upside from current levels. In a report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.
Based on Innate Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.86 million and a GAAP net loss of $21.34 million. In comparison, last year the company earned a revenue of $12.35 million and had a GAAP net loss of $24.76 million
Read More on IPHA:
Disclaimer & DisclosureReport an Issue
- Innate Pharma management to meet with BTIG
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
- Innate Pharma SA Reports First Half 2025 Financial Results
- Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
